Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Conditions
Brief summary
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine the overall response rate (ORR) to axitinib in advanced melanoma. This will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. SECONDARY OBJECTIVES: I. Evaluate toxicity of axitinib as a single agent. II. Determine progression-free survival and overall survival. III. Explore the utility of 3'-deoxy-3'-\[18F\] fluorothymidine-labeled positron emission tomography (FLT-PET) as a predictive marker for response and compare to standard radiographic imaging. TERTIARY OBJECTIVES: I. Examine the prognostic and predictive significance of circulating melanoma tumor cells. II. To examine whether functionally relevant polymorphisms in axitinib-related genes (vascular endothelial growth factor receptor \[VEGFR\] 1, VEGFR2 and VEGFR3) correlate with efficacy and toxicity of axitinib in advanced melanoma. OUTLINE: Patients receive axitinib orally (PO) twice daily (BID). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days.
Interventions
DRUGaxitinib
Given PO
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
National Comprehensive Cancer Network
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically proven melanoma (including uveal) that is advanced (metastatic) or unresectable * Measurable disease * No more than two prior regimens (0-2) of systemic therapy for metastatic or recurrent disease; therapy (systemic or radiotherapy) administered in the neo-adjuvant or adjuvant setting for previously localized disease is permitted, provided it was completed more than 3 months prior to enrollment; palliative radiotherapy is permitted provided it is completed \>= 2 weeks prior to study therapy initiation and there is at least one measurable lesion outside the radiation field; at least 2 weeks since the end of prior systemic treatment, radiotherapy, or surgical procedure with resolution of all treatment-related toxicity to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade =\< 1 or back to baseline except for alopecia or hypothyroidism * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Life expectancy \>= 12 weeks * Absolute neutrophil count (ANC) \>= 1500 cells/mm\^3 * Platelets \>= 75,000 cells/mm\^3 * Hemoglobin \>= 9.0 g/dL * Creatinine =\< 1.5 X upper limit normal (ULN) or calculated creatinine clearance \>= 60 mL/min * Bilirubin =\< 1.5 X ULN * Transaminase =\< 2.5 X ULN (for documented liver metastases, transaminase up to 5 X ULN is permitted) * Random urinary protein/creatinine ratio \< 2 * Have the ability to swallow and retain oral medication * No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart; the baseline systolic blood pressure readings must be =\< 140 mm Hg, and the baseline diastolic blood pressure readings must be =\< 90 mm Hg; patients whose hypertension is controlled by antihypertensive therapies are eligible * Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment * Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment and for 6 months following completion of study treatment * Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board (IRB) approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Prior anti-angiogenic therapy * Major surgery \< 4 weeks or radiation therapy \< 2 weeks of starting the study treatment; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least 1 measurable lesion that has not been irradiated * Significant history of bleeding events (e.g., hemoptysis, grade 3 or grade 4 gross hematuria) within 6 months prior to registration * Presence of serious non-healing wounds, ulcers (including gastro-intestinal) and bone fractures * Gastrointestinal abnormalities including: * Inability to take oral medication * Requirement for intravenous alimentation * Prior surgical procedures affecting absorption including total gastric resection; segmental small bowel or colon resection is permitted * Treatment for active peptic ulcer disease in the past 6 months * Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 6 months without evidence of resolution documented by endoscopy or colonoscopy * Malabsorption syndromes * History of gastrointestinal (GI) perforation within prior 12 months * Current use or anticipated need for treatment with drugs that are known potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine) * Current use or anticipated need for treatment with drugs that are known CYP3A4 or cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2) inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St. John's wort) * Requirement of therapeutic anticoagulant therapy with oral vitamin K antagonists; low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed; therapeutic use of low molecular weight heparin (or similar parenteral drug) for venous-thromboembolic disease is allowed * Active seizure disorder or evidence of untreated brain metastases, spinal cord compression, or carcinomatous meningitis; patients with brain metastases that have been stable for \>= 4 weeks by radiographic documentation following definitive therapy will be permitted provided this is not the only site of metastatic disease * Arterial thrombotic events within 6 months of registration, including myocardial infarction, unstable angina or angina requiring medical or surgical intervention in the past 6 months, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack and clinically significant peripheral vascular disease (i.e., claudication on less than 1 block) * Current congestive heart failure (New York Heart Association \[NYHA\] class II, III or IV) * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness * History of a malignancy except those treated with curative intent for skin cancer (other than melanoma), in-situ breast or in-situ cervical cancer, or those treated with curative intent for any other cancer with no evidence of disease for 3 years * Female patients who are pregnant or lactating * Received an investigational agent within 30 days prior to enrollment * A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment * Any condition which in the investigator's opinion would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (Complete Response + Partial Response) to Axitinib as Assessed Using RECIST Version 1.1 | Up to 30 days | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients That Experienced at Least One Grade 3 Adverse Event | Up to 30 days | Number of patients that experienced at least one grade 3 toxicity regardless of attribution. Incidence of toxicity of axitinib as a single agent as assessed by the severity of adverse effects by NCI CTCAE version 4. Please refer to the adverse event reporting for more detail. |
| Median Progression-free Survival (PFS) | From the date of study enrollment to the first observation of progressive disease or death within 30 days after last dose of study drug | The distribution will be described using Kaplan-Meier and proportional hazards methods. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Median Overall Survival (OS) | From the date of study enrollment to the time of death within 30 days after last dose of study drug | The distribution will be described using Kaplan-Meier and proportional hazards methods. |
| The Baseline Circulative Tumor Cells Value of Responders | Baseline | The baseline Circulative tumor Cells values of patients with response to treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. CTC were evaluated at baseline, response was assessed up to 30 days. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Axitinib) Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
axitinib: Given PO
The starting dose for axitinib is 5 mg taken orally twice daily with food. Axitinib will be taken beginning on Day 1 of the study and taken approximately 12 hours apart continuous dosing.
Dose Level Dose Dispensed As
* 2: 10 mg PO BID 2 X 5 mg tablets BID
* 1: 7 mg PO BID 1 X 5 mg tablet BID + 2 X 1 mg tablets BID 0: (Starting Dose) 5 mg PO BID 1 X 5 mg tablet BID
* 1: 3 mg PO BID 3 X 1 mg tablets BID
* 2: 2 mg PO BID 2 X 1 mg tablets BID | 25 |
| Total | 25 |
Baseline characteristics
| Characteristic | Treatment (Axitinib) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 15 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants |
| Age, Continuous | 68.8 years STANDARD_DEVIATION 11.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 25 Participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 25 / 25 |
| serious Total, serious adverse events | 8 / 25 |
Outcome results
Primary
Overall Response Rate (Complete Response + Partial Response) to Axitinib as Assessed Using RECIST Version 1.1
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 30 days
Population: All treated and eligible patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Axitinib) | Overall Response Rate (Complete Response + Partial Response) to Axitinib as Assessed Using RECIST Version 1.1 | 12 percentage of participants |
Secondary
Median Overall Survival (OS)
The distribution will be described using Kaplan-Meier and proportional hazards methods.
Time frame: From the date of study enrollment to the time of death within 30 days after last dose of study drug
Population: All treated and eligible patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Axitinib) | Median Overall Survival (OS) | 7.4 months |
Secondary
Median Progression-free Survival (PFS)
The distribution will be described using Kaplan-Meier and proportional hazards methods. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: From the date of study enrollment to the first observation of progressive disease or death within 30 days after last dose of study drug
Population: All treated and eligible patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Axitinib) | Median Progression-free Survival (PFS) | 2.1 months |
Secondary
Number of Patients That Experienced at Least One Grade 3 Adverse Event
Number of patients that experienced at least one grade 3 toxicity regardless of attribution. Incidence of toxicity of axitinib as a single agent as assessed by the severity of adverse effects by NCI CTCAE version 4. Please refer to the adverse event reporting for more detail.
Time frame: Up to 30 days
Population: All treated and eligible patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Axitinib) | Number of Patients That Experienced at Least One Grade 3 Adverse Event | 12 Participants |
Secondary
The Baseline Circulative Tumor Cells Value of Responders
The baseline Circulative tumor Cells values of patients with response to treatment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. CTC were evaluated at baseline, response was assessed up to 30 days.
Time frame: Baseline
Population: All treated and eligible patients that responded
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Treatment (Axitinib) | The Baseline Circulative Tumor Cells Value of Responders | 0 cells/mm^3 | Standard Deviation 0 |